How Many Vascular Biogenics Ltd. (NASDAQ:VBLT)’s Analysts Are Bullish?

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 2 analysts covering Vascular Biogenics (NASDAQ:VBLT), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Vascular Biogenics has $3 highest and $200 lowest target. $2.50’s average target is 95.31% above currents $1.28 stock price. Vascular Biogenics had 4 analyst reports since March 19, 2019 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, March 19 by Chardan Capital Markets. Below is a list of Vascular Biogenics Ltd. (NASDAQ:VBLT) latest ratings and price target changes.

27/06/2019 Broker: Oppenheimer Rating: Outperform New Target: $2.0000 Initiates Coverage On
19/05/2019 Broker: BidaskScore Rating: Sell Downgrade
14/04/2019 Broker: BidaskScore Rating: Hold Downgrade
19/03/2019 Broker: Chardan Capital Markets Rating: Hold New Target: $3 Maintain

The stock increased 1.59% or $0.02 during the last trading session, reaching $1.28. About 8,680 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has declined 32.31% since September 13, 2018 and is downtrending. It has underperformed by 32.31% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $45.93 million. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

More notable recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: which released: “VBL Therapeutics to Present at Upcoming Conferences in April – GlobeNewswire” on March 25, 2019, also with their article: “Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates – Yahoo Finance” published on May 15, 2019, published: “VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR – GlobeNewswire” on April 16, 2018. More interesting news about Vascular Biogenics Ltd. (NASDAQ:VBLT) were released by: and their article: “VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan – GlobeNewswire” published on November 06, 2017 as well as‘s news article titled: “Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates – Yahoo Finance” with publication date: August 13, 2019.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.